スタチンは,閉経後の女性のエストロゲン置換療法中のC反応性タンパク質の増加を弱める
Kwang Kon Koh1, William H Schenke, Myron A Waclawiw
1Gachon Medical College, Inchon, South Korea.
Circulation
|April 3, 2002
まとめ
スタチンを経口エストロゲンと併用することで,閉経後の女性の有害な炎症を軽減することができます. このスタチンとエストロゲンの併用療法により,エストロゲン単独で投与されたときに見たC反応性タンパク質 (CRP) 濃度の上昇を弱めた.
科学分野:
- 心血管医学 心血管医学
- エンドクリノロジー エンドクリノロジー
- 薬理学 薬理学とは
背景:
- HMG-CoA還元酵素阻害剤 (スタチン) 治療は,低C反応性タンパク質 (CRP) レベルによって示される動脈炎症を減少させることで,潜在的に心血管リスクを減らすことが知られている.
- 経口エストロゲンは,閉経後の女性のCRPを増加させ,炎症と血栓形成のリスクを高め,心臓血管の恩恵を相殺する可能性があります.
- この研究では,スタチンの併用がCRPに対するエストロゲン効果を修正できるかどうかを調査した.
研究 の 目的:
- スタチン治療が閉経後の女性のC反応性タンパク質 (CRP) レベルに対する経口エストロゲンの炎症効果を軽減できるかどうかを判断する.
- 結合馬性エストロゲン (CEEs) とシムバスタチンを併用することで,CRPレベルに及ぼす影響を評価する.
主な方法:
- 28人の閉経後の女性を対象とした3期間のクロスオーバー研究.
- 参加者は6週間の間隔で6週間の洗浄間隔で隔てられた6週間の期間,毎日0.625mgの結合馬性エストロゲン (CEEs),シムバスタチン10mg,または組み合わせを投与されました.
- CRPレベルの変化を測定し,治療グループ間で比較した.
主要な成果:
- CEEだけでは,中位CRP濃度 (0.27から0.46 mg/dL) を有意に増加させました.
- シムバスタチン単独では,CRP濃度がわずかに低下した (0.29から0.28mg/dL).
- 併用療法はCRPを増加させた (0.28から0.36mg/dL),しかし,この増加は,CEE単独で観察されたもの (70%) よりも (29%) はるかに少なかった.
結論:
- スタチンをエストロゲン療法と併用すると,閉経後の女性のエストロゲンの潜在的有害な炎症効果を弱める可能性があります.
- この組み合わせは,心血管疾患のリスク軽減の利点を最大化するのに役立ちます.
- この研究は,ホルモン療法を用いた閉経後の女性の心血管リスクを管理するための潜在的な戦略を示唆しています.
関連する概念動画
Hormonal Regulation
37.6K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
37.6K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.7K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.7K
Drugs for Treatment of Constipation-Predominant IBS
1.4K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
927
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
927
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
820
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
820
Intestinal Phase of Digestion
10.1K
The intestinal phase of digestion is the third and final stage of the digestive process, occurring after the cephalic and gastric phases. It begins when chyme, a partially digested mixture of food and digestive enzymes, enters the small intestine from the stomach. This phase is crucial for nutrient absorption and involves complex hormonal and enzymatic interactions.
The arrival of the chyme in the small intestine distends the duodenum, which triggers the enterogastric reflex. This distension...
The arrival of the chyme in the small intestine distends the duodenum, which triggers the enterogastric reflex. This distension...
10.1K


